中文产业新闻精选评分80Chinese source
FDA批准first-in-class TYK2/JAK1抑制剂Lisraya（brepocitinib）用于成人皮肌炎
美国FDA今日批准“first-in-class”TYK2/JAK1抑制剂 | 产业新闻
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.
美国FDA今日批准“first-in-class”TYK2/JAK1抑制剂 | 产业新闻
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.